Is Denali Therapeutics (DNLI) A Smart Long-Term Investment?
Baron Funds, an asset management firm, published its “Baron Growth Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.
Denali Therapeutics Inc. (DNLI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Integral Health Asset Management Bhagwan Jay Rao | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 275,000 | Large Shareholder | 19,462,499 | 2017-12-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.15 | 200 | Director | 1,950,356 | 2022-07-25 | Filing | |
| $35.60 | 19,800 | Director | 1,950,556 | 2022-07-25 | Filing | |
| $34.14 | 11,598 | Director | 2,024,370 | 2022-03-23 | Filing | |
| $33.40 | 8,402 | Director | 2,035,968 | 2022-03-23 | Filing | |
| $34.14 | 11,598 | Director | 2,024,370 | 2022-03-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 14,869,374 | $437,606 | 0.45% | |
| 2. | 322,882 | $9,502 | 0.07% | |
| 3. | 222,420 | $6,546 | 0.25% | |
| 4. | 140,829 | $4,145 | 0% | |
| 5. | 121,223 | $3,568 | 0% |
News See All
Do Hedge Funds Love Denali Therapeutics Inc. (DNLI)?
In this article we are going to use hedge fund sentiment as a tool and determine whether Denali Therapeutics Inc. (NASDAQ:DNLI) is a good investment right now.
Should You Now Liquidate Your Denali Therapeutics (DNLI) Position?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” third quarter 2021 investor letter – a copy of which can be downloaded here.
5 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital
Below is the list of 5 pharmaceutical stocks to buy according to Jim Simons’ Euclidean Capital.
Here is What Hedge Funds Think About Denali Therapeutics Inc. (DNLI)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
8 Best Stocks to Buy According to Billionaire Nicholas J. Pritzker's Tao Capital
In this article, we will be discussing 8 best stocks to buy according to billionaire Nicholas J. Pritzker based on his hedge fund's Q1 portfolio. To skip our detailed analysis of Nicholas J.
5 Best Pharma and Biotech Stocks to Buy According to Jim Simons' Euclidean Capital
In this article, we discuss the 5 best pharma and biotech stocks to buy according to Jim Simons' Euclidean Capital.
Where Do Hedge Funds Stand On Denali Therapeutics Inc. (DNLI)?
In this article we will check out the progression of hedge fund sentiment towards Denali Therapeutics Inc. (NASDAQ:DNLI) and determine whether it is a good investment right now.
10 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson
In this article we will take a look at the 10 best pharmaceutical stocks to buy according to billionaire Kerr Neilson.
Is Denali Therapeutics Inc. (DNLI) A Smart Long-Term Buy?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here.
Billionaire Hedge Funds
